Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov;12(11):2881-2901.
doi: 10.1080/21645515.2016.1210729. Epub 2016 Jul 25.

Viral vector-based influenza vaccines

Rory D de Vries  1 , Guus F Rimmelzwaan  1
Affiliations

Viral vector-based influenza vaccines

Rory D de Vries et al. Hum Vaccin Immunother. 2016 Nov.

Abstract

Antigenic drift of seasonal influenza viruses and the occasional introduction of influenza viruses of novel subtypes into the human population complicate the timely production of effective vaccines that antigenically match the virus strains that cause epidemic or pandemic outbreaks. The development of game-changing vaccines that induce broadly protective immunity against a wide variety of influenza viruses is an unmet need, in which recombinant viral vectors may provide. Use of viral vectors allows the delivery of any influenza virus antigen, or derivative thereof, to the immune system, resulting in the optimal induction of virus-specific B- and T-cell responses against this antigen of choice. This systematic review discusses results obtained with vectored influenza virus vaccines and advantages and disadvantages of the currently available viral vectors.

Keywords: MVA; adenovirus; immunity; influenza; vaccine; vector.

PubMed Disclaimer

References

    1. Murphy BR, Kasel JA, Chanock RM. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 1972; 286:1329-32; PMID:5027388; http://dx.doi.org/ 10.1056/NEJM197206222862502 - DOI - PubMed
    1. Nichol KL. Live attenuated influenza virus vaccines: new options for the prevention of influenza. Vaccine 2001; 19:4373-7; PMID:11483261; http://dx.doi.org/ 10.1016/S0264-410X(01)00143-8 - DOI - PubMed
    1. Gilca R, Skowronski DM, Douville-Fradet M, Amini R, Boulianne N, Rouleau I, Martineau C, Charest H, De Serres G. Mid-Season estimates of influenza vaccine effectiveness against influenza A(H3N2) hospitalization in the elderly in Quebec, Canada, January 2015. PLoS One 2015; 10:e0132195; PMID:26200655; http://dx.doi.org/ 10.1371/journal.pone.0132195 - DOI - PMC - PubMed
    1. Pebody RG, Warburton F, Ellis J, Andrews N, Thompson C, von Wissmann B, Green HK, Cottrell S, Johnston J, de Lusignan S, et al.. Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. Euro Surveill 2015; 20:21025; PMID:25677050; http://dx.doi.org/ 10.2807/1560-7917.ES2015.20.5.21025 - DOI - PubMed
    1. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, Drews SJ, Fonseca K, Charest H, Gubbay JB, et al.. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill 2015; 20(4):21022; PMID:25655053; http://dx.doi.org/ 10.2807/1560-7917.ES2015.20.4.21022 - DOI - PubMed

Publication types

MeSH terms